Viking Therapeutics stock jumps nearly 30% after drugmaker moves weight loss injection to late-stage trial
It brings the drugmaker one step closer to joining the market for GLP-1s, which analysts say could grow into a $150 billion market by the end of the decade.
It brings the drugmaker one step closer to joining the market for GLP-1s, which analysts say could grow into a $150 billion market by the end of the decade.
